Skip to main content

Table 3 Comparison of main outcome measures by study arm, Boromo Health District, Burkina Faso (2004–2006)

From: A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso

  Study arms Comparisons
  Intervention     
Characteristic A B Control A vs. Control B vs. Control A vs. B
   % (n/N)    OR (95%CI)  
Antenatal care       
≥ 3 ANC visits 62.3 (463/743) 42.3 (339/801) 45.8 (341/744) 1.95 (0.86–4.45) 0.87 (0.36–2.10) 2.25 (0.86–5.92)
1st ANC visit in third trimester † 18.7 (127/679) 28.5 (199/699) 30.8 (205/666) 0.52 (0.26–1.03) 0.90 (0.47–1.70) 0.58** (0.44–0.76)
≥ 2 doses IPT-SP 69.9 (519/743) 48.6 (389/801)     2.45* (1.25–4.82)
Home visit at 32 weeks       
Anaemia (PCV < 33) 49.4 (288/583) 48.7 (285/585) 56.4 (299/530) 0.75 (0.37–1.54) 0.73 (0.36–1.50) 1.03 (0.68–1.56)
Moderate/severe anaemia (PCV < 30) 23.8 (139/583) 27.7 (162/585) 30.2 (160/530) 0.72 (0.39–1.34) 0.89 (0.45–1.73) 0.82 (0.62–1.08)
Peripheral parasitaemia 20.3 (121/597) 19.4 (120/618) 29.9 (167/558) 0.60* (0.39–0.91) 0.56** (0.40–0.80) 1.05 (0.67–1.67)
Delivery       
Anaemia (PCV < 33) ‡ 31.1 (137/440) 32.8 (131/399) 40.2 (150/373) 0.67 (0.38–1.18) 0.73 (0.39–1.36) 0.92 (0.51–1.69)
Moderate/severe anaemia (PCV < 30) ‡ 16.8 (74/440) 16.8 (67/399) 19.8 (74/373) 0.82 (0.46–1.46) 0.82 (0.46–1.46) 1.00 (0.58–1.72)
Peripheral parasitaemia‡ 17.4 (87/499) 20.1 (95/472) 33.3 (144/432) 0.42*** (0.30–0.60) 0.50** (0.37–0.69) 0.84 (0.60–1.18)
Placental parasitaemia 18.1 (89/491) 20.5 (90/440) 30.3 (131/432) 0.51** (0.37–0.70) 0.59* (0.44–0.78) 0.86 (0.58–1.29)
Low birth weight (< 2500 grams) § 16.2 (95/585) 18.6 (128/687) 22.3 (132/593) 0.68 (0.42–1.08) 0.80 (0.46–1.39) 0.85 (0.61–1.17)
Miscarriage/stillbirths || 5.5 (41/742) 4.1 (33/801) 4.9 (36/742) 1.15 (0.89–1.48) 0.84 (0.55–1.28) 1.36 (0.88–2.12)
  1. Intervention A = IPTp+promotion; Intervention B = IPTp alone; Control = CQ chemoprophylaxis; ANC = antenatal care; PCV = packed cell volume; OR = odds ratio; CI = confidence interval.
  2. The non-adjusted risk estimates are presented as these did not change when adjusted for possible confounders.
  3. * p < 0.05; ** p < 0.01; *** p < 0.001;
  4. † singleton live-births only;
  5. ‡ only samples taken the day of delivery;
  6. § live born singletons weighed within 8 days after delivery;
  7. || 3 maternal deaths not included